Factors associated with achieving minimally symptomatic status by patients with schizophrenia: results from the 3-year intercontinental schizophrenia outpatients health outcomes study



This article is corrected by:

  1. Errata: Erratum Volume 64, Issue 10, 1459, Article first published online: 16 August 2010

  • Disclosures Tamás Treuer, Ferenc Martenyi and Yulia Dyachkova are employees of Eli Lilly and Company, the manufacturer of olanzapine. Mete Saylan is a former employee of Eli Lilly and Company. The authors have no additional financial interest to declare.

Dr Tamás Treuer, Neuroscience Research, Eli Lilly & Company, H-1075 Budapest, Madach Imre u 13-14, Hungary
Tel.: + 3613285127
Fax: + 3613285103
Email: treuert@lilly.com


Objective:  The aim of this study was to describe factors associated with achieving a minimally symptomatic status outcome in outpatients with schizophrenia.

Methods:  Data were analysed from a 3-year, prospective observational study that examined outcomes in 7658 patients with schizophrenia. Minimally symptomatic status was defined as a postbaseline score of 1 or 2 on the Clinical Global Impressions Severity Scale-Schizophrenia version (CGI-SCH).

Results:  Baseline CGI-SCH score had the strongest association with minimally symptomatic status followed by age, geographical region and hospitalisation status. The probability of becoming minimally symptomatic was consistently higher in the olanzapine and clozapine monotherapy groups compared with the quetiapine, risperidone or haloperidol groups. The olanzapine group achieved the minimally symptomatic status in a shorter period of time than the other treatment groups (p ≤ 0.016).

Conclusion:  The likelihood of patients achieving a minimally symptomatic status was greater in younger patients with lower baseline clinical severity and in patients whose treatment included olanzapine.